Richard Anthony Cunningham - 16 Sep 2022 Form 4 Insider Report for TYME TECHNOLOGIES, INC. (TYME)

Role
Chief Executive Officer
Signature
By: /s/ Richard Cunningham
Issuer symbol
TYME
Transactions as of
16 Sep 2022
Transactions value $
$0
Form type
4
Filing time
16 Sep 2022, 18:00:32 UTC
Previous filing
26 Apr 2022
Next filing
11 Oct 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TYME Employee Stock Option - Option to buy Disposed to Issuer -2,000,000 -100% 0 16 Sep 2022 Common Stock 2,000,000 $1.03 Direct F1
transaction TYME Employee Stock Option - Option to buy Disposed to Issuer -500,000 -100% 0 16 Sep 2022 Common Stock 500,000 $1.43 Direct F2
transaction TYME Employee Stock Option - Option to buy Disposed to Issuer -1,326,000 -100% 0 16 Sep 2022 Common Stock 1,326,000 $0.33 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Richard Anthony Cunningham is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 This option was fully vested and assumed by Syros Pharmaceuticals, Inc. ("Syros") in its merger with the issuer and replaced with an option to purchase 87,640 shares of Syros common stock for $23.51 per share, after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split").
F2 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 21,910 shares of Syros common stock for $32.63 per share, after giving effect to the Reverse Split.
F3 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 58,105 shares of Syros common stock for $7.53 per share, after giving effect to the Reverse Split.